Chikungunya Fever: Advances in Epidemiology, Pathogenesis & Vaccine Development (2025)
A recent suspension of the IXCHIQ vaccine license has prompted renewed scrutiny of global efforts to combat chikungunya virus, an increasingly widespread arboviral disease. The suspension, stemming from safety concerns, comes as the virus continues to expand its reach, with 119 countries and territories reporting local transmission as of 2024.
Chikungunya is transmitted primarily by Aedes aegypti and Aedes albopictus mosquitoes. The virus causes a range of symptoms, beginning with the abrupt onset of fever, severe joint pain, swelling, muscle aches, and rash. While most individuals recover within weeks, a significant proportion experience persistent arthralgia or chronic arthritis lasting months or even years, contributing substantially to the overall disease burden.
The re-emergence of chikungunya over the past two decades has been observed across Africa, Asia, the Indian Ocean, Europe, and the Americas. This expansion is attributed to a widening geographic range and increased susceptibility within larger populations. Recent outbreaks have spurred research into the disease’s pathogenesis, host immune responses, and the mechanisms driving chronic inflammation.
Beyond the challenges posed by the virus itself, vaccine development has faced setbacks. While both IXCHIQ, a live-attenuated vaccine, and VIMKUNYA, a virus-like particle vaccine, had previously been approved, the suspension of IXCHIQ’s license underscores the complexities of creating a safe and effective preventative measure. The Conversation reported on the growing concern surrounding the virus in Australia, highlighting the global nature of the threat.
Research continues to focus on understanding the intricacies of CHIKV infection, including its impact on host receptors and the potential for mother-to-child transmission. A recent global situation report from NaTHNaC indicates ongoing surveillance and monitoring of the virus’s spread. The Centers for Disease Control and Prevention (CDC) has as well issued information regarding the rising incidence of dengue fever, a related mosquito-borne illness, emphasizing the broader public health challenges posed by vector-borne diseases.
A study published in Nature detailed vector surveillance efforts during a major chikungunya outbreak in northwestern São Paulo state, Brazil, providing insights into the dynamics of transmission in a real-world setting. These findings contribute to a growing body of knowledge aimed at improving control strategies and mitigating the impact of chikungunya virus disease.